The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
Capsules, Oral, Single Dose, 1 day
Capsules, Oral, 0mg, Single Dose, 1 day
Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
Ppd Development, Lp
Austin, Texas, United States
Adverse events (AEs), vital signs, electrocardiogram (ECG) and clinical laboratory test results
Time frame: Within the 10 days after study drug administration
Pharmacokinetic profile (drug absorption, distribution, metabolism and excretion process) determined by plasma concentration vs. time profile from a series of plasma samples up to 10 days post dose
Time frame: Within the 10 days after study drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days